I reckon they will, it would have been unusual for them to get approval straight up from the FDA, they usually have a few questions on trial protocols. Pretty cheap entry price here and they will be reapplying (or already have) for IND with the FDA, whichever, it can only be weeks or a month or two away. An approval to start the Phase2 trial in America will see this stock shoot the lights out. This is Alzheimers, novel and has great independent science backing it. Gets me excited just typing it.
I reckon they will, it would have been unusual for them to get...
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
